The cardiac prosthetic devices market size has grown rapidly in recent years. It will grow from $9.09 billion in 2025 to $10.13 billion in 2026 at a compound annual growth rate (CAGR) of 11.4%. The growth in the historic period can be attributed to rising prevalence of cardiovascular diseases, increasing incidence of heart valve disorders, growth in cardiac surgical procedures, expanding availability of cardiac care centers, improving clinical outcomes of prosthetic heart devices.
The cardiac prosthetic devices market size is expected to see rapid growth in the next few years. It will grow to $15.57 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to aging global population, increasing demand for minimally invasive cardiac treatments, rising burden of heart failure cases, expanding access to advanced cardiac care in emerging markets, growing focus on early intervention for structural heart diseases. Major trends in the forecast period include rising adoption of minimally invasive cardiac prosthetic procedures, increasing demand for advanced heart valve replacement solutions, growing use of cardiac prosthetics in heart failure management, expansion of transcatheter cardiac device applications, increasing focus on long-term device durability and patient outcomes.
The growing prevalence of cardiovascular diseases is expected to drive the expansion of the cardiac prosthetic devices market. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, such as coronary artery disease, heart attacks, and strokes. The rise in cardiovascular diseases can be attributed to unhealthy lifestyles, high obesity rates, poor dietary habits, lack of exercise, high stress levels, and an aging population. Cardiac prosthetic devices are crucial in managing these diseases by supporting or replacing heart functions or its components. For example, in January 2024, data from the British Heart Foundation, a UK-based cardiovascular research charity, revealed that approximately 7.6 million people in the UK are affected by heart and circulatory diseases. This includes around 4 million men and 3.6 million women. These conditions contribute to about 27% of all deaths in the UK, resulting in more than 170,000 deaths annually, or approximately 480 deaths per day - roughly one death every three minutes. As a result, the rising prevalence of cardiovascular diseases is driving growth in the cardiac prosthetic devices market.
Major companies operating in the cardiac prosthetic devices market are concentrating on minimally invasive transcatheter therapies, such as transcatheter edge-to-edge repair (TEER) systems, which are catheter-based clip implants engineered to capture and bring together the leaflets of a malfunctioning valve (such as the tricuspid valve), thereby minimizing regurgitation without the need for open-heart surgery. For instance, in April 2024, Abbott, a U.S.-based medical technology company, introduced its TriClip G4 System, a TEER device designed to treat severe tricuspid regurgitation. The TriClip G4 System is delivered through a femoral-vein catheter; its clip arms are designed to open and close to secure the valve leaflets, and the system allows the use of multiple clips to achieve optimal reduction of valve leakage.
In October 2024, Johnson & Johnson, a U.S.-based diversified medical technology and pharmaceutical company, acquired V-Wave Ltd. for an undisclosed sum; through this acquisition, Johnson & Johnson sought to enhance and expand its cardiac prosthetic and structural heart portfolio by incorporating V-Wave’s Ventura® implantable interatrial shunt for heart failure, thereby strengthening its range of minimally invasive cardiac implants and improving therapeutic options for patients with advanced heart failure. V-Wave Ltd. is an Israel-based cardiovascular medical device company specializing in the development of implantable interatrial shunt devices for the treatment of heart failure.
Major companies operating in the cardiac prosthetic devices market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, BIOTRONIK SE & Co KG, Terumo Corporation, Lepu Medical Technology Beijing Co Ltd, Abiomed Inc, LivaNova PLC, Meril Life Sciences Pvt Ltd, MicroPort Scientific Corporation, CryoLife Inc, LifeTech Scientific Corporation, Venus Medtech Hangzhou Inc, Braile Biomedica, AtriCure Inc, Aortic Innovations Inc, Pacetronix Limited, TTK Healthcare Limited, Kawasumi Laboratories Inc.
North America was the largest region in the cardiac prosthetic devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac prosthetic devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac prosthetic devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the cardiac prosthetic devices market by increasing costs for imported medical-grade materials, electronic components, and precision-engineered parts used in valves and pacemakers. These added costs have affected procurement and pricing, particularly for transcatheter heart valves and advanced pacemaker systems, with north america and europe being more exposed due to complex global supply chains. Higher tariffs have modestly slowed device adoption in cost-sensitive healthcare settings. However, tariffs have also encouraged local manufacturing, supplier diversification, and regional production capabilities, supporting long-term supply chain resilience.
The cardiac prosthetic devices market research report is one of a series of new reports that provides cardiac prosthetic devices market statistics, including cardiac prosthetic devices industry global market size, regional shares, competitors with a cardiac prosthetic devices market share, detailed cardiac prosthetic devices market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac prosthetic devices industry. This cardiac prosthetic devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cardiac prosthetic devices are medical devices designed to support or replace the function or components of the heart. They are crucial for treating various cardiac conditions and managing patients with heart failure or structural heart issues.
The main types of cardiac prosthetic devices include valves and pacemakers. Valves are artificial devices implanted in the heart to replace malfunctioning natural heart valves. They are used in applications such as surgery and research and serve various end users, including hospitals, clinics or cardiac centers, ambulatory surgical centers, and other medical facilities.
The cardiac prosthetic devices market consists of sales of ventricular assist devices, implantable cardioverter defibrillators, and cardiac resynchronization therapy devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The cardiac prosthetic devices market size is expected to see rapid growth in the next few years. It will grow to $15.57 billion in 2030 at a compound annual growth rate (CAGR) of 11.3%. The growth in the forecast period can be attributed to aging global population, increasing demand for minimally invasive cardiac treatments, rising burden of heart failure cases, expanding access to advanced cardiac care in emerging markets, growing focus on early intervention for structural heart diseases. Major trends in the forecast period include rising adoption of minimally invasive cardiac prosthetic procedures, increasing demand for advanced heart valve replacement solutions, growing use of cardiac prosthetics in heart failure management, expansion of transcatheter cardiac device applications, increasing focus on long-term device durability and patient outcomes.
The growing prevalence of cardiovascular diseases is expected to drive the expansion of the cardiac prosthetic devices market. Cardiovascular diseases (CVDs) encompass a range of disorders affecting the heart and blood vessels, such as coronary artery disease, heart attacks, and strokes. The rise in cardiovascular diseases can be attributed to unhealthy lifestyles, high obesity rates, poor dietary habits, lack of exercise, high stress levels, and an aging population. Cardiac prosthetic devices are crucial in managing these diseases by supporting or replacing heart functions or its components. For example, in January 2024, data from the British Heart Foundation, a UK-based cardiovascular research charity, revealed that approximately 7.6 million people in the UK are affected by heart and circulatory diseases. This includes around 4 million men and 3.6 million women. These conditions contribute to about 27% of all deaths in the UK, resulting in more than 170,000 deaths annually, or approximately 480 deaths per day - roughly one death every three minutes. As a result, the rising prevalence of cardiovascular diseases is driving growth in the cardiac prosthetic devices market.
Major companies operating in the cardiac prosthetic devices market are concentrating on minimally invasive transcatheter therapies, such as transcatheter edge-to-edge repair (TEER) systems, which are catheter-based clip implants engineered to capture and bring together the leaflets of a malfunctioning valve (such as the tricuspid valve), thereby minimizing regurgitation without the need for open-heart surgery. For instance, in April 2024, Abbott, a U.S.-based medical technology company, introduced its TriClip G4 System, a TEER device designed to treat severe tricuspid regurgitation. The TriClip G4 System is delivered through a femoral-vein catheter; its clip arms are designed to open and close to secure the valve leaflets, and the system allows the use of multiple clips to achieve optimal reduction of valve leakage.
In October 2024, Johnson & Johnson, a U.S.-based diversified medical technology and pharmaceutical company, acquired V-Wave Ltd. for an undisclosed sum; through this acquisition, Johnson & Johnson sought to enhance and expand its cardiac prosthetic and structural heart portfolio by incorporating V-Wave’s Ventura® implantable interatrial shunt for heart failure, thereby strengthening its range of minimally invasive cardiac implants and improving therapeutic options for patients with advanced heart failure. V-Wave Ltd. is an Israel-based cardiovascular medical device company specializing in the development of implantable interatrial shunt devices for the treatment of heart failure.
Major companies operating in the cardiac prosthetic devices market are Abbott Laboratories, Medtronic plc, Boston Scientific Corporation, Edwards Lifesciences Corporation, BIOTRONIK SE & Co KG, Terumo Corporation, Lepu Medical Technology Beijing Co Ltd, Abiomed Inc, LivaNova PLC, Meril Life Sciences Pvt Ltd, MicroPort Scientific Corporation, CryoLife Inc, LifeTech Scientific Corporation, Venus Medtech Hangzhou Inc, Braile Biomedica, AtriCure Inc, Aortic Innovations Inc, Pacetronix Limited, TTK Healthcare Limited, Kawasumi Laboratories Inc.
North America was the largest region in the cardiac prosthetic devices market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac prosthetic devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac prosthetic devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the cardiac prosthetic devices market by increasing costs for imported medical-grade materials, electronic components, and precision-engineered parts used in valves and pacemakers. These added costs have affected procurement and pricing, particularly for transcatheter heart valves and advanced pacemaker systems, with north america and europe being more exposed due to complex global supply chains. Higher tariffs have modestly slowed device adoption in cost-sensitive healthcare settings. However, tariffs have also encouraged local manufacturing, supplier diversification, and regional production capabilities, supporting long-term supply chain resilience.
The cardiac prosthetic devices market research report is one of a series of new reports that provides cardiac prosthetic devices market statistics, including cardiac prosthetic devices industry global market size, regional shares, competitors with a cardiac prosthetic devices market share, detailed cardiac prosthetic devices market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac prosthetic devices industry. This cardiac prosthetic devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Cardiac prosthetic devices are medical devices designed to support or replace the function or components of the heart. They are crucial for treating various cardiac conditions and managing patients with heart failure or structural heart issues.
The main types of cardiac prosthetic devices include valves and pacemakers. Valves are artificial devices implanted in the heart to replace malfunctioning natural heart valves. They are used in applications such as surgery and research and serve various end users, including hospitals, clinics or cardiac centers, ambulatory surgical centers, and other medical facilities.
The cardiac prosthetic devices market consists of sales of ventricular assist devices, implantable cardioverter defibrillators, and cardiac resynchronization therapy devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Cardiac Prosthetic Devices Market Characteristics
3. Cardiac Prosthetic Devices Market Supply Chain Analysis
4. Global Cardiac Prosthetic Devices Market Trends and Strategies
5. Cardiac Prosthetic Devices Market Analysis of End Use Industries
7. Global Cardiac Prosthetic Devices Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Cardiac Prosthetic Devices Total Addressable Market (TAM) Analysis for the Market
9. Cardiac Prosthetic Devices Market Segmentation
10. Cardiac Prosthetic Devices Market Regional and Country Analysis
11. Asia-Pacific Cardiac Prosthetic Devices Market
12. China Cardiac Prosthetic Devices Market
13. India Cardiac Prosthetic Devices Market
14. Japan Cardiac Prosthetic Devices Market
15. Australia Cardiac Prosthetic Devices Market
16. Indonesia Cardiac Prosthetic Devices Market
17. South Korea Cardiac Prosthetic Devices Market
18. Taiwan Cardiac Prosthetic Devices Market
19. South East Asia Cardiac Prosthetic Devices Market
20. Western Europe Cardiac Prosthetic Devices Market
21. UK Cardiac Prosthetic Devices Market
22. Germany Cardiac Prosthetic Devices Market
23. France Cardiac Prosthetic Devices Market
24. Italy Cardiac Prosthetic Devices Market
25. Spain Cardiac Prosthetic Devices Market
26. Eastern Europe Cardiac Prosthetic Devices Market
27. Russia Cardiac Prosthetic Devices Market
28. North America Cardiac Prosthetic Devices Market
29. USA Cardiac Prosthetic Devices Market
30. Canada Cardiac Prosthetic Devices Market
31. South America Cardiac Prosthetic Devices Market
32. Brazil Cardiac Prosthetic Devices Market
33. Middle East Cardiac Prosthetic Devices Market
34. Africa Cardiac Prosthetic Devices Market
36. Cardiac Prosthetic Devices Market Competitive Landscape and Company Profiles
37. Cardiac Prosthetic Devices Market Other Major and Innovative Companies
40. Cardiac Prosthetic Devices Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Cardiac Prosthetic Devices Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses cardiac prosthetic devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for cardiac prosthetic devices? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The cardiac prosthetic devices market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Valves; Pacemakers2) By Applications: Surgery; Heart Valve Replacement Procedures; Cardiac Rhythm Management
3) By End User: Hospitals; Clinics Or Cardiac Centers; Ambulatory Surgical Centers; Other End-Users
Subsegments:
1) By Valves: Mechanical Valves; Tissue Valves; Transcatheter Heart Valves2) By Pacemakers: Single-Chamber Pacemakers; Dual-Chamber Pacemakers; Biventricular Pacemakers
Companies Mentioned: Abbott Laboratories; Medtronic plc; Boston Scientific Corporation; Edwards Lifesciences Corporation; BIOTRONIK SE & Co KG; Terumo Corporation; Lepu Medical Technology Beijing Co Ltd; Abiomed Inc; LivaNova PLC; Meril Life Sciences Pvt Ltd; MicroPort Scientific Corporation; CryoLife Inc; LifeTech Scientific Corporation; Venus Medtech Hangzhou Inc; Braile Biomedica; AtriCure Inc; Aortic Innovations Inc; Pacetronix Limited; TTK Healthcare Limited; Kawasumi Laboratories Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Cardiac Prosthetic Devices market report include:- Abbott Laboratories
- Medtronic plc
- Boston Scientific Corporation
- Edwards Lifesciences Corporation
- BIOTRONIK SE & Co KG
- Terumo Corporation
- Lepu Medical Technology Beijing Co Ltd
- Abiomed Inc
- LivaNova PLC
- Meril Life Sciences Pvt Ltd
- MicroPort Scientific Corporation
- CryoLife Inc
- LifeTech Scientific Corporation
- Venus Medtech Hangzhou Inc
- Braile Biomedica
- AtriCure Inc
- Aortic Innovations Inc
- Pacetronix Limited
- TTK Healthcare Limited
- Kawasumi Laboratories Inc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 10.13 Billion |
| Forecasted Market Value ( USD | $ 15.57 Billion |
| Compound Annual Growth Rate | 11.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 21 |
